Zimmer Biomet board approves $1.5B stock repurchase program

On February 9, Zimmer Biomet’s (ZBH) Board of Directors approved a new stock repurchase authorization, granting the company authority to repurchase up to $1.5B in common stock. The new authorization commences on February 9, 2026 and has no expiration date. Under the program, which is designed to return value to Zimmer Biomet’s shareholders and minimize dilution from stock issuances, the company may repurchase shares in the open market and enter into structured repurchase agreements with third parties.